Collegium Pharmaceutical, Inc. - Common Stock (COLL)
35.82
+0.11 (0.31%)
NASDAQ · Last Trade: Oct 23rd, 11:32 AM EDT
Detailed Quote
Previous Close
35.71
Open
35.60
Bid
35.76
Ask
35.92
Day's Range
35.58 - 36.11
52 Week Range
23.23 - 39.95
Volume
43,062
Market Cap
1.16B
PE Ratio (TTM)
34.44
EPS (TTM)
1.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
343,770
Chart
About Collegium Pharmaceutical, Inc. - Common Stock (COLL)
Collegium Pharmaceutical is a biotechnology company that focuses on developing innovative treatments for pain management and related conditions. The company specializes in formulating and bringing to market unique drug delivery systems and therapies that aim to enhance patient outcomes while addressing issues like opioid misuse and dependence. By leveraging advanced technology and scientific research, Collegium strives to provide healthcare professionals and patients with effective and safer alternatives for managing acute and chronic pain, contributing to improving overall quality of life. Read More
STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Collegium Pharmaceutical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 10%. The stock now trades at $35.02, marking a 34.7% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neuroscience Education Institute (NEI) conferences.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical (NASDAQ:COLL) and the rest of the branded pharmaceuticals stocks fared in Q2.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV, September 2-5, 2025. The posters will highlight real-world data from the company’s portfolio of pain treatments and reflect Collegium’s continued commitment to responsible pain management.
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s full-year revenue guidance of $752.5 million at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.68 per share was 9.2% below analysts’ consensus estimates.
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s full-year revenue guidance of $752.5 million at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.68 per share was 9.2% below analysts’ consensus estimates.
Collegium Pharmaceutical (COLL) reports strong Q2 2025 earnings, beating estimates with $188M revenue (+29% YoY) and $1.68 EPS. Raised full-year guidance and new $150M buyback program signal growth momentum.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026. This program replaces a previous $150 million share repurchase program authorized in January 2024 which expired on June 30, 2025, and had $65 million remaining under the program.
